Lombard Odier Asset Management USA Corp Sells 1,941 Shares of Cencora, Inc. $COR

Posted by Geri Gentry on Jul 26th, 2026

Lombard Odier Asset Management USA Corp lowered its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 31.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,171 shares of the company’s stock after selling 1,941 shares during the period. Lombard Odier Asset Management USA Corp’s holdings in Cencora were worth $1,310,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Cencora by 160.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after buying an additional 4,123,795 shares in the last quarter. Norges Bank bought a new stake in shares of Cencora in the 4th quarter valued at $822,506,000. Marshall Wace LLP increased its stake in shares of Cencora by 518.9% in the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after acquiring an additional 1,672,762 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after acquiring an additional 1,241,186 shares during the period. Finally, Viking Global Investors LP lifted its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Shares of COR opened at $309.67 on Friday. The business’s fifty day moving average is $284.52 and its 200 day moving average is $316.47. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The stock has a market cap of $60.25 billion, a P/E ratio of 23.75, a P/E/G ratio of 1.72 and a beta of 0.58.

Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the firm posted $4.42 EPS. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Cencora declared that its board has initiated a share repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on COR. Bank of America increased their target price on shares of Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 24th. UBS Group lifted their price target on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Barclays dropped their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. William Blair started coverage on shares of Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Finally, Morgan Stanley set a $342.00 target price on Cencora in a research note on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $367.75.

Check Out Our Latest Analysis on COR

Insider Activity at Cencora

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.38% of the stock is currently owned by insiders.

Cencora Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.